Prasugren HCl, irreversibly inhibits the P2Y12 receptors, inhibiting ADP-dependent platelet activation[3]. Prasugrel might have a better efficacy profile than ticagrelor in patients with ACS (acute coronary syndrome) undergoing PCI (percutaneous coronary intervention) [4]. In antiplatelet therapy after aneurysmal interventional therapy, the second generation of P2Y12 adenosine receptor antagonist prasugrel can significantly reduce the risk of thrombosis without increasing the risk of bleeding[5]. Laboratory studies and early phase clinical trials show prasugrel has a faster onset of action, is more potent and has reduced inter-patient response variability compared to clopidogrel[6]. Prasugrel and ticagrelor are more efficacious than clopidogrel in reducing the occurrence of non-fatal myocardial infarction, stroke, or cardiovascular (CV) death but they have also an increased risk of major bleeding in comparison to clopidogrel[7].
搜索
